These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17671722)

  • 1. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells.
    Hamacher R; Saur D; Fritsch R; Reichert M; Schmid RM; Schneider G
    Oncol Rep; 2007 Sep; 18(3):695-701. PubMed ID: 17671722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by down-regulation of casein kinase 2 in prostate cancer cells.
    Ahmad KA; Wang G; Ahmed K
    Mol Cancer Res; 2006 May; 4(5):331-8. PubMed ID: 16687488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.
    Schneider CC; Hessenauer A; Montenarh M; Götz C
    Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Casein kinase 2 regulates both apoptosis and the cell cycle following DNA damage induced by 6-thioguanine.
    Yamane K; Kinsella TJ
    Clin Cancer Res; 2005 Mar; 11(6):2355-63. PubMed ID: 15788687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.
    Di Maira G; Brustolon F; Bertacchini J; Tosoni K; Marmiroli S; Pinna LA; Ruzzene M
    Oncogene; 2007 Oct; 26(48):6915-26. PubMed ID: 17486073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation.
    Yamane K; Kinsella TJ
    Cancer Res; 2005 May; 65(10):4362-7. PubMed ID: 15899828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells.
    Hessenauer A; Montenarh M; Götz C
    Int J Oncol; 2003 Jun; 22(6):1263-70. PubMed ID: 12738992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
    Raaf J; Brunstein E; Issinger OG; Niefind K
    Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casein Kinase II: an attractive target for anti-cancer drug design.
    Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
    Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of protein kinase CK2 as oncological target.
    Seeber S; Issinger OG; Holm T; Kristensen LP; Guerra B
    Apoptosis; 2005 Aug; 10(4):875-85. PubMed ID: 16133877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibitory effect of AG1109 on recombinant human protein kinase CK2 holoenzyme].
    Liu XG; Liang NC
    Ai Zheng; 2002 Feb; 21(2):153-7. PubMed ID: 12479065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme].
    Li CM; Liu XG; Lin XC; Chen XW; Liang NC
    Ai Zheng; 2008 Aug; 27(8):809-15. PubMed ID: 18710613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
    Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
    Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Protein kinase CK2 and cancer: further clues are accumulating].
    Filhol O; Cochet C
    Bull Cancer; 2002 Mar; 89(3):261-5. PubMed ID: 11940465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resorufin: a lead for a new protein kinase CK2 inhibitor.
    Sandholt IS; Olsen BB; Guerra B; Issinger OG
    Anticancer Drugs; 2009 Apr; 20(4):238-48. PubMed ID: 19177021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2.
    Martel V; Filhol O; Colas P; Cochet C
    Oncogene; 2006 Nov; 25(56):7343-53. PubMed ID: 16751801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro.
    Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Kazimierczuk Z; Grieb P; Stepien H
    Cell Tissue Res; 2010 May; 340(2):371-9. PubMed ID: 20383646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells.
    Melstrom LG; Salabat MR; Ding XZ; Milam BM; Strouch M; Pelling JC; Bentrem DJ
    Pancreas; 2008 Nov; 37(4):426-31. PubMed ID: 18953257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.